Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP

Birth prevalence of achondroplasia: A systematic literature review and meta‐analysis

(2020) Pamela K. Foreman et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

(2020) Ravi Savarirayan et al.   LANCET

TransCon CNP, a sustained-release C-Type Natriuretic Peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with FGFR3-related skeletal dysplasias

(2019) Vibeke Miller Breinholt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Growth in achondroplasia: Development of height, weight, head circumference, and body mass index in a European cohort

(2018) Andrea Merker et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Development of body proportions in achondroplasia: Sitting height, leg length, arm span, and foot length

(2018) Andrea Merker et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial IntegrityNovelty and Significance

(2017) Kazuhiro Nakao et al.   HYPERTENSION

Fibroblast growth factor signaling in skeletal development and disease

(2015) David M. Ornitz et al.   GENES & DEVELOPMENT

Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes

(2014) Zi-Qiang Zhou et al.   HUMAN MOLECULAR GENETICS

Evaluation of the Therapeutic Potential of a CNP Analog in a Fgfr3 Mouse Model Recapitulating Achondroplasia

(2012) Florence Lorget et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Analysis of STAT1 Activation by Six FGFR3 Mutants Associated with Skeletal Dysplasia Undermines Dominant Role of STAT1 in FGFR3 Signaling in Cartilage

(2008) Pavel Krejci et al.   PLoS One